<i>PHD2</i> Mutation and Congenital Erythrocytosis with Paraganglioma

Charline Ladroue, Romain Carcenac, M Leporrier, Sophie Gad, C. Le Hello, Françoise Galateau-Sallé, Jean Feunteun, Jacques Pouysségur, Betty Gardie

New England Journal of Medicine · 2008 · 319 citations · 19 references

DOIFull text

Open access

Concepts

Abstract

Prolyl hydroxylase domain (PHD) proteins play a major role in regulating the hypoxia-inducible factor (HIF) that induces expression of genes involved in angiogenesis, erythropoiesis, and cell metabolism, proliferation, and survival. Germ-line mutations in the prolyl hydroxylase domain 2 gene (PHD2) have been reported in patients with familial erythrocytosis but not in association with tumors. We describe a patient with erythrocytosis and recurrent paraganglioma who carries a newly discovered PHD2 mutation. This mutation affects PHD2 function and stabilizes HIF-alpha proteins. In addition, we demonstrate loss of heterozygosity of PHD2 in the tumor, suggesting that PHD2 could be a tumor-suppressor gene.

References

19